CYBN 11.41 Cybin Inc.
| Range: | 6.5-28.044 | Vol Avg: | 183053 | Last Div: | 0 | Changes: | 0.96 |
| Beta: | 0.91 | Cap: | 0.23B | Currency: | USD | Exchange: | AMEX |
| Sector: | Healthcare | IPO: | Fri Sep 13 2019 | Empoloyees: | 50 | ||
| CUSIP: | 23256X100 | CIK: | 0001833141 | ISIN: | CA23256X1006 | Country: | CA |
| CEO: | Mr. Douglas L. Drysdale | Website: | https://www.cybin.com | ||||
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Stock Details
Positive 0.22
Cybin: Top Value Psychedelic Stock
Cybin is a promising value investment, with advanced clinical trials and strong institutio...
seekingalpha.com·Tue Oct 15 2024
Positive 0.34
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “...
businesswire.com·Thu Oct 03 2024
Positive 0.54
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “...
businesswire.com·Tue Oct 01 2024
Positive 0.53
Cybin Provides Corporate Update on Upcoming Clinical Milestones
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “...
businesswire.com·Thu Sep 19 2024
Positive 0.22
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxie...
seekingalpha.com·Thu Sep 19 2024
Positive 0.48
Cybin Announces Completion of Previously Announced Share Consolidation
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the ...
businesswire.com·Thu Sep 19 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow